Items where authors include "Foltynie, T."

Article

Gonzalez-Robles, C. orcid.org/0000-0001-6809-0127, Athauda, D. orcid.org/0000-0001-8594-2483, Barber, T.R. et al. (26 more authors) (2025) Treatment selection and prioritization for the EJS ACT-PD MAMS trial platform. Movement Disorders, 40 (7). pp. 1307-1317. ISSN 0885-3185

Chelban, V. orcid.org/0000-0002-7797-0756, Pellerin, D., Vijiaratnam, N. orcid.org/0000-0002-9671-0212 et al. (50 more authors) (2025) Intronic FGF14 GAA repeat expansions impact progression and survival in multiple system atrophy. Brain. ISSN 0006-8950

Arena, G. orcid.org/0000-0003-2398-5503, Landoulsi, Z., Grossmann, D. et al. (19 more authors) (2024) Polygenic risk scores validated in patient‐derived cells stratify for mitochondrial subtypes of Parkinson's disease. Annals of Neurology, 96 (1). pp. 133-149. ISSN 0364-5134

Gonzalez-Robles, C., Weil, R.S., van Wamelen, D. et al. (20 more authors) (2023) Outcome measures for disease-modifying trials in Parkinson’s disease: consensus paper by the EJS ACT-PD multi-arm multi-stage trial initiative. Journal of Parkinson's Disease, 13 (6). pp. 1011-1033. ISSN 1877-7171

Payne, T., Appleby, M., Buckley, E. et al. (16 more authors) (2023) A double‐blind, randomized, placebo‐controlled trial of ursodeoxycholic acid (UDCA) in Parkinson's disease. Movement Disorders, 38 (8). pp. 1493-1502. ISSN 0885-3185

Foltynie, T. orcid.org/0000-0003-0752-1813, Gandhi, S., Gonzalez-Robles, C. et al. (85 more authors) (2023) Towards a multi-arm multi-stage platform trial of disease modifying approaches in Parkinson’s disease. Brain, 146 (7). pp. 2717-2722. ISSN 0006-8950

Payne, T., Sassani, M., Buckley, E. et al. (12 more authors) (2020) Ursodeoxycholic acid as a novel disease-modifying treatment for Parkinson’s disease: protocol for a two-centre, randomised, double-blind, placebo-controlled trial, The 'UP' study. BMJ Open, 10 (8). e038911. ISSN 2044-6055